- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03755869
Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line(ALTER-L020)
April 1, 2020 updated by: First Affiliated Hospital Xi'an Jiaotong University
An Open, Single-arm, Multi-center Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line Chemotherapy
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development.
It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor celltebiz related kinase -c-Kit kinase.
In the phase III study, Patients who failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib (12mg, po.
qd. on day 1to14 of a 21-day cycle) or placebo, the anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months.
Study Overview
Detailed Description
It is an open, single-arm, multi-center clinical trial conducted in China, and plan to Recruiting103 patients who were progressed after first line systemic therapy and refused/can't tolerate chemotherapy.
Patents receive 12mg anlotinib orally daily on day 1to 14 of a 21-day cycle until progression of disease, assess safety and efficacy of the drug.
Study Type
Interventional
Enrollment (Anticipated)
103
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: enxiao li, professor
- Phone Number: 0086-13992819833
- Email: doclienxiao@sina.com
Study Contact Backup
- Name: jingjing miao
- Phone Number: 0086-18392055301
- Email: miaojing0403@163.com
Study Locations
-
-
Shanxi
-
Xian, Shanxi, China, 710000
- Recruiting
- Shaanxi Provincial Cancer Hospital
-
Contact:
- minhui wu, doctor
- Phone Number: 13891825509
- Email: wuminhui@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed and dated informed consent
- Age:18~75 years;
- Subjects with histologically or cytologically confirmed locally advanced and/or advanced NSCLC
- at least two systematic chemotherapy with upwards of 1-line treatments or cannot suffer
- The negative patients in EGFR&ALK can participate or who positive in EGFR&ALK, have or have not drug tolerance after the treatment with relative targeted drugs
- Subjects with at least one measurable lesion as defined by RECIST (version 1.1)
- Expected Survival Time: Over 3 months
- ECOG PS:0-1,
- main organs function is normal
- The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it
Exclusion Criteria:
- 1.Small Cell Lung Cancer (including small cell cancer and other kinds of cancer mixed with non-small cell cancer)
- lung squamous carcinoma
- Other active malignancies requiring treatment
- History of malignancy
- Have got non remissive toxic reactions derived from previous therapies, which is over level 1 in CTC AE (4.0), alopecia NOT included
- Abnormal coagulation (INR>1.5 or PT>ULN+4s or APTT >1.5 ULN); Patients with any physical signs of bleeding diathesis or receiving thrombolysis and anticoagulation
- take major surgical treatments or have serious trauma before grouping, or the impact of surgery or trauma has been eliminated for less than 14 days.
- Patients with active or unable to control serious infections;
- Patients with Grade II or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QTc male ≥ 450 ms, female ≥ 470 ms) ; Patients with grade III to IV cardiac insufficiency, or left ventricular ejection fraction (LVEF) <50% (NYHA Classification)
- Patients with non-healing wounds or fractures
- with kinds of factors which affect oral medicine (e.g. failing to swallow, gastrointestinal tract getting resected, chronic diarrhea and ileus).
- get arterial/venous thrombosis within 12 months, such as cerebrovascular accidents (including temporary ischemic stoke), deevenous thrombosis, and pulmonary embolism
- plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the medicine-taking period of this research, including Cytotoxic Therapy, Signal Transduction Inhibitor, and Immunotherapy
- Patients with cirrhosis, decompensated liver disease, or active hepatitis Have suffered from hemorrhagic disease or coagulation dysfunction
- diagnosed with disease which will severely endanger the security of patients or influence the completion of this research
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anlotinib
Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
|
Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning.
If patients cannot suffer from AEs, they can get declined dosage.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1
Time Frame: Baseline until PD or death, whichever occurs first (up to approximately 24 months)
|
Progress free survival (PFS)
|
Baseline until PD or death, whichever occurs first (up to approximately 24 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Overall Survival (OS) as Assessed by the Investigator Using RECIST v1.1
Time Frame: Baseline until death from any cause (up to approximately 24 months)
|
Overall Survival (OS)
|
Baseline until death from any cause (up to approximately 24 months)
|
Disease Control Rate (DCR)as Assessed by the Investigator Using RECIST v1.1
Time Frame: First occurrence of PR or CR until PD or death, whichever occurs first (up to 24 months)
|
Disease Control Rate (DCR)
|
First occurrence of PR or CR until PD or death, whichever occurs first (up to 24 months)
|
Objective Response Rate (ORR) as Assessed by the Investigator Using RECIST v1.1
Time Frame: Baseline until partial response (PR) or complete response (CR), whichever occurs first (up to 24 months)
|
Objective Response Rate (ORR)
|
Baseline until partial response (PR) or complete response (CR), whichever occurs first (up to 24 months)
|
Percentage of Participants with Adverse Events
Time Frame: Baseline until up to 21 days after end of treatment
|
Percentage of Participants with Adverse Events
|
Baseline until up to 21 days after end of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: enxiao li, professor, First Affiliated Hospital Xi'an Jiaotong University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 29, 2018
Primary Completion (Anticipated)
November 1, 2021
Study Completion (Anticipated)
December 1, 2021
Study Registration Dates
First Submitted
November 26, 2018
First Submitted That Met QC Criteria
November 27, 2018
First Posted (Actual)
November 28, 2018
Study Record Updates
Last Update Posted (Actual)
April 3, 2020
Last Update Submitted That Met QC Criteria
April 1, 2020
Last Verified
April 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XJTU1AF2018LSK-073
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-squamous NSCLC
-
Jair Bar, M.D., Ph.D.Not yet recruiting
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
Jiangsu Cancer Institute & HospitalNot yet recruiting
-
Shanghai Chest HospitalMerck Sharp & Dohme LLCRecruitingNon-squamous NSCLCChina
-
Michael HoppBoehringer IngelheimActive, not recruiting
-
PfizerTerminatedAdvanced Non-squamous NSCLCChina
-
LanZhou UniversityGeneral Hospital of Ningxia Medical UniversityUnknown
-
Hunan Province Tumor HospitalCompletedNon-squamous NSCLCChina
-
Guangdong Association of Clinical TrialsUnknownAdvanced Non-squamous NSCLCChina
-
AmgenTerminatedAdvanced Non-squamous NSCLC
Clinical Trials on Anlotinib
-
First People's Hospital of HangzhouChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent High-grade GliomaChina
-
Peng YuanCompletedBreast Neoplasm | Antineoplastic Agents | AnlotinibChina
-
Peking Union Medical College HospitalRecruitingPheochromocytoma | ParagangliomaChina
-
Peking Union Medical College HospitalRecruitingParaganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, MalignantChina
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Non-small Cell Lung Cancer | Lung NeoplasmChina
-
Sun Yat-sen UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Small Cell Lung Cancer | Lung NeoplasmChina
-
Hunan Cancer HospitalFuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...RecruitingSmall Cell Lung CancerChina
-
Peking Union Medical College HospitalRecruiting
-
Sun Yat-sen UniversityRecruitingSarcoma,Soft TissueChina